Serum Apolipoprotein J in Health, Coronary Heart Disease and Type 2 Diabetes Mellitus

• Published in: Journal of Atherosclerosis and Thrombosis 2006, Vol.13(6), pp.314-322
• Main Authors: Kujiraoka, Takeshi, Hattori, Hiroaki, Miwa, Yoshikazu, Ishihara, Mitsuaki, Ueno, Takahiro, Ishii, Jun, Tsuji, Masahiro, Iwasaki, Tadao, Sasaguri, Yoshiyuki, Fujioka, Takayuki, Saito, Satoshi, Tsushima, Motoo, Maruyama, Taro, Miller, Irina P, Miller, Norman E, Egashira, Tohru
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - immunology; Clusterin; Clusterin - blood; Clusterin - immunology; Coronary Disease - blood; Coronary heart disease; Diabetes Mellitus, Type 2 - blood; Enzyme-Linked Immunosorbent Assay - methods; Enzyme-Linked Immunosorbent Assay - standards; Female; Humans; Male; Middle Aged; Paraoxonase; Reference Values; Type 2 diabetes mellitus
• ISSN: 1340-3478; 1880-3873
• DOI: 10.5551/jat.13.314

Apolipoprotein (apo) J, clusterin, is ubiquitously expressed in many tissues, and is a component of high-density lipoproteins (HDLs). There is experimental evidence that it may be anti-atherogenic through its effects on cholesterol transport, smooth muscle cell proliferation and lipid peroxidation. HDLs containing apo J and apo A-I carry paraoxonase (PON1), which protects low-density lipoproteins from oxidative modification; however, the extent to which apo J affects coronary heart disease (CHD) is not known. We have developed a sandwich ELISA that enables apo J to be assayed in the range of 13-200 µg/mL. Serum apo J was 52.8±0.8 µg/mL (mean±SEM; range, 36.0-84.3 µg/mL; n=92) in healthy Japanese men, and 49.3±0.5 µg/mL (34.5-72.8; n=241) in healthy Japanese women. Multiple regression of these data and results from 67 men with CHD showed that apo J concentration was unrelated to age, sex or body mass index, but was positively related to serum PON1 (p